Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
03/23/2020 03/24/2020 03/25/2020 03/26/2020 03/27/2020 Date
4.5(c) 4.772(c) 4.796(c) 4.65(c) 4.778(c) Last
1 328 351 676 348 388 532 478 084 372 173 Volume
+11.17% +6.04% +0.50% -3.04% +2.75% Change
More quotes
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -16,3 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
Sales 2020 119 M
EBIT 2020 -59,9 M
Net income 2020 -48,3 M
Finance 2020 92,5 M
Yield 2020 -
P/E ratio 2019 -34,6x
P/E ratio 2020 -95,6x
EV / Sales2019 3,62x
EV / Sales2020 2,39x
Capitalization 377 M
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune... 
More about the company
Surperformance© ratings of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on INNATE PHARMA
03/10INNATE PHARMA : First patient dosed in IPH5201 Phase I clinical trial in advance..
AQ
03/10INNATE PHARMA : reports full year 2019 financial results and business update
GL
03/10First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumor..
GL
03/10INNATE PHARMA : Annual results
CO
03/10INNATE PHARMA : Slide show results
CO
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/29Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
01/14INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
01/13French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitme..
GL
01/13INNATE PHARMA : French regulatory agency agrees lacutamab TELLOMAK trial can res..
GL
01/09Tesla vindicated, Apple enjoys success in China, Boeing’s troubles continue…
01/09INNATE PHARMA : Provides update from regulatory agencies on lacutamab tellomak t..
GL
01/09Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK ..
GL
01/03INNATE PHARMA : SA - The European Medicines Agency accepts the regulatory submis..
AQ
More news
News in other languages on INNATE PHARMA
03/13INNATE PHARMA : plus forte baisse du marché SRD à la clôture du vendredi 13 mars..
03/10STOCK MARKET PARIS : Un rebond fragile après la débâcle
03/10Les valeurs à suivre aujourd'hui à la Bourse de Paris Mardi 10 mars 2020
03/10INNATE PHARMA : premier patient traité dans un essai évaluant IPH5201
03/10INNATE PHARMA : 2019, année structurante
More news
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 11,92  €
Last Close Price 4,78  €
Spread / Highest target 226%
Spread / Average Target 149%
Spread / Lowest Target 88,4%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-19.83%418
LONZA GROUP11.21%29 660
IQVIA HOLDINGS INC.-30.66%20 658
CELLTRION, INC.3.08%20 147
SEATTLE GENETICS, INC.-4.37%18 823
INCYTE CORPORATION-16.34%14 949